Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs?

Bibliography

• FRAME S, COHEN P: GSK-3 takes centre stage more than 20 years after its discovery. Biochem. (2001) 359:1–16.
   Google Scholar
• LAU KF, MILLER CC, ANDERTON BH, SHAW PC: Expression analysis of glycogen synthase kinase-3 in human tissues. J. Pept. Res. (1999) 54:85–91.
   PubMedGoogle Scholar
• MUKAI F, ISHIGURO K, SANO Y, FUJITA SC: Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase-313.1. Neurochem (2002) 81:1073–1083.
   PubMed Web of Science ®Google Scholar
• GRIMES CA, JOPE RS: The multifaceted roles of glycogen synthase kinase-3I3 in cellular signalling. Prog. Neurobiol. (2001) 65:391–426.
   PubMed Web of Science ®Google Scholar
• ••Presents a complete description of thebiological functions of GSK-3.
   Google Scholar
• LUCAS JJ, HERNANDEZ F, GOMEZ-RAMOS P, MORAN MA, HEN R, AVILA J: Decreased nuclear I3-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3I3 conditional transgenic mice. EMBO J. (2001) 20:27–39.
   PubMed Web of Science ®Google Scholar
• ••Describes the in vivo experiments thatvalidate GSK-3 as a target for neurodegenerative disorders.
   Google Scholar
• KAYTOR MD, ORR HT: The GSK-3I3 signalling cascade and neurodegenerative disease. Carr. Opin. Neurob. (2002) 12:275–278.
   PubMed Web of Science ®Google Scholar
• CASTRO A, MARTINEZ A: Inhibition of tau phosphorylation: a new therapeutic strategy for the treatment of Alzheimer's disease and other neurodegenerative disorders. Exp. Opin. Ther. Patents (2000) 10:1519–1527.
   Web of Science ®Google Scholar
• LI X, BIJUR GN, JOPE RS: Glycogen synthase kinase-3I3, mood stabilizers, and neuroprotection. Bipolar Disord. (2002) 4:37–144.
   PubMedGoogle Scholar
• MARTINEZ A, CASTRO A, DORRONSORO I, ALONSO M: Glycogen synthase kinase-3I3 (GSK-3I3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer and inflammation. Med. Res. Rev. (2002) 22:373–384.
   PubMed Web of Science ®Google Scholar
• •Reviews the scientific literature surrounding small molecule GSK-3 inhibitors.
   Google Scholar
• COHEN P, FRAME S: The renaissance of GSK-3. Nat. Rev (2001) 2:769–776.
   Google Scholar
• •Highlights the potential of GSK-3 as a new therapeutic target as well as the properties desirable for its inhibitors.
   Google Scholar
• YOST C, FARR GH, PIERCE SB, FERKEY DM, CHEN MM, KIMELMAN D: GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. Cell (1998) 93:1031–1041.
   PubMed Web of Science ®Google Scholar
• PEREZ C, VAZQUEZ J, AVILA J, MORENO FJ. P24, a glycogen synthase kinase-3 (GSK-3) inhibitor. Biochim. Biophys. Acta (2002) 1586:113–122.
   PubMedGoogle Scholar
• TER HAAR E, COLL JT, AUSTEN DA, HSIAO HM, SWENSON L, JAIN J: Structure of GSK-3I3 reveals a primed phosphorylation mechanism. Nat. Struc. Biol. (2001) 8:593–596.
   PubMedGoogle Scholar
• DAJANI R, FRASER E, ROE SM et al.: Crystal structure of glycogen synthase kinase-313: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell (2001) 105:721–732.
   PubMed Web of Science ®Google Scholar
• BAX B, CARTER PS, LEWIS C et al: Thestructure of phosphorylated GSK-3I3 complexed with a peptide, FRATtide, that inhibits P-catenin phosphorylation. Structure (2001) 9:1143–1152.
   PubMed Web of Science ®Google Scholar
• HERS I, TAVARE JM, DENTON RM: The protein kinase C inhibitors bisindolylmaleimide I (GF109203X) and IX (Ro 31-8220) are potent inhibitors of glycogen kinase-3 activity. FEBS lett (1990) 460:433–436.
   Google Scholar
• SMITH DG, BUFFET M, FENWICK AE et al.: 3-Anilino-4-arylmaleimides: Potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett (2001) 11:635–639.
   PubMed Web of Science ®Google Scholar
• COGHLAN MP, CULBERT AA, CROSS DAE et al: Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. (2000) 7:793–803.
   PubMed Web of Science ®Google Scholar
• CROSS DAE, CUBERT AA, CHALMERS KA, FACCI L, SKAPER SD, REITH AD: Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protects primary neurones from death." Neurochem. (2001) 77:94–102.
   PubMedGoogle Scholar
• BARNES PJ: Cytokine modulators as novel therapies for asthma. Anna. Rev. Pharmaco. Toxic°. (2002) 42:81–98.
   PubMed Web of Science ®Google Scholar
• MEIJER L, THUNNISSEN AM, WHITE AW et al.: Inhibition of cyclin-dependent kinases, GSK-3I3 and CK1 by hymenaldisine, a marine sponge constituent. Chem. Biol. (2000) 7:51–63.
   PubMed Web of Science ®Google Scholar
• BRETON JJ, CHABOT-FLETCHER MC: The natural product hymenaldisine inhibits interleukin-8 production in U937 cells by inhibition of nuclear factor-KB. J. Pharmacol Exp. Ther. Patents (1997) 282:459–466.
   PubMedGoogle Scholar
• ZAHAREVITZ DW, GUSSIO R, LEOST M et al.: Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res. (1999) 1:60–67.
   Google Scholar
• LECLERC S, GARNIER M, HOESSEL R et al: Indirubins inhibit glycogen synthase kinase-3I3 and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors..! Biol. Chem. (2001) 276:251–260.
   Google Scholar
• MARTINEZ A, ALONSO M, CASTRO A, PEREZ C, MORENO FJ: First non-ATP competitive glycogen synthase kinase-3I3 (GSK-3I3) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease." Med. Chem. (2002) 45(6):1292–1299.
   Google Scholar
• MARTINEZ A, CASTRO A, CARDELUS I, LLENAS J, PALACIOS JM: Arylimino-1,2,4-thidiazolidinones: a new family of potassium channel openers. Bioorg. Med. Chem. (1997) 5:1275–1283.
   PubMedGoogle Scholar
• MARTINEZ A, ALONSO D, CASTRO A et al: Synthesis and potential muscarinic receptor binding and antioxidant properties of 3-(thiadiazolyl)pyridine 1-oxide compounds. Arch. Pharm. (1999) 332:191–194.
   PubMed Web of Science ®Google Scholar
• MARTINEZ A, FERNANDEZ E, CASTRO A et al.: N-benzylpiperidine derivatives of 1,2,4-thiadiazolidinone as new acetylcholinesterase inhibitors. Eur. J. Med. Chem: (2000) 35:913–922.
   Google Scholar
• CASTRO A, CONDE S, RODRIGUEZ-FRANCO MI, MARTINEZ A: Non-cholinergic pharmacotharapy approaches to the future treatment of Alzheimer's disease. Mini Rev Med. Chem. (2002) 2:37–50.
   PubMed Web of Science ®Google Scholar
• MACCIONI RB, MUNOZ JP, BARBEITO L: The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch. Med. Res. (2001) 32:367–381.
   PubMed Web of Science ®Google Scholar
• GOTZ J: Tau and transgenic animal models. Brain Res. Rev (2001) 35:266–286.
   PubMedGoogle Scholar
• HERNANDEZ F, LIM F, LUCAS JJ et al.: Transgenic mouse models with tau pathology to test therapeutic agents for Alzheimer's disease. Mini Rev. Med. Chem. (2002) 2:51–58.
   PubMedGoogle Scholar
• ALI A, HOEFLICH KP, WOODGETT JR: Glycogen synthase kinase-3: Properties, functions and regulation. Chem.Rev. (2001) 101:2527–2540.
   PubMedGoogle Scholar
• http://www.stke.org/cgi/content/full/ OC_sigtrans;2001/100/re12 WOOD GETT JR: Judging a protein by morethan its name: GSK-3. Sciencg STKE (2001)
   Google Scholar